Market Place
Sourcing Support
Seres Therapeutics Reports Q3 2024 Financial Results & Updates
13 Nov 2024 //
GLOBENEWSWIRE
Seres Therapeutics to Announce Q3 2024 Financials & Updates
06 Nov 2024 //
GLOBENEWSWIRE
Seres Therapeutics Completes VOWST Sale To Société Nestlé S.A
30 Sep 2024 //
GLOBENEWSWIRE
Seres Therapeutics Stockholders Issue Open Letter To Board
27 Sep 2024 //
BUSINESSWIRE
Seres Therapeutics Stockholders Approve Sale Of VOWST
26 Sep 2024 //
GLOBENEWSWIRE
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
13 Sep 2024 //
GLOBENEWSWIRE
Seres Reports SER-155 Phase 1b Results In Allo-HSCT Patients
12 Sep 2024 //
GLOBENEWSWIRE
Seres Therapeutics Reports Q2 2024 Results And Business Updates
13 Aug 2024 //
GLOBENEWSWIRE
Seres Therapeutics To Announce Q2 2024 Results On August 13
06 Aug 2024 //
GLOBENEWSWIRE
Seres Therapeutics Signs VOWST Asset Purchase With Nestlé
06 Aug 2024 //
GLOBENEWSWIRE
Seres Therapeutics Reports Inducement Grants
07 Jun 2024 //
GLOBENEWSWIRE
Nestle bids to take control of Seres’ C diff drug Vowst
07 Jun 2024 //
PHARMAPHORUM
CDSCO panel gives nod for continuation of ph-II trial of SII`s dengue vaccine
06 Jun 2024 //
ECONOMICTIMES
Nestlé To Acquire Global Rights To VOWST® From Seres
06 Jun 2024 //
PR NEWSWIRE
Seres, Nestlé Ink MoU For Potential Vowst™ Asset Sale
06 Jun 2024 //
GLOBENEWSWIRE
Seres Therapeutics: Q1 2024 Financials, Business Updates
08 May 2024 //
BUSINESSWIRE
Seres Therapeutics Inducement Grants Under Nasdaq Rule
06 May 2024 //
BUSINESSWIRE
Seres Therapeutics to update financials and business on May 8, 2024.
06 May 2024 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Mar 2024 //
BUSINESSWIRE
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
BUSINESSWIRE
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
27 Feb 2024 //
BUSINESSWIRE
Seres Therapeutics Announces the Appointment of Marella Thorell as CFO
26 Feb 2024 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Jan 2024 //
BUSINESSWIRE
Seres to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
Seres Therapeutics Announces Presentation of Safety Data for SER-155
07 Dec 2023 //
BUSINESSWIRE
Seres to Participate in the Piper Sandler 35th Annual Healthcare Conference
28 Nov 2023 //
BUSINESSWIRE
Seres slims R&D, staff to focus on approved microbiome drug
02 Nov 2023 //
FIERCE BIOTECH
Seres Therapeutics to Highlight VOWST™ Data at IDWeek
12 Oct 2023 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Oct 2023 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Sep 2023 //
BUSINESSWIRE
Seres to Participate in Morgan Stanley 21st Annual Global Healthcare Conference
07 Sep 2023 //
BUSINESSWIRE
Seres Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 //
BUSINESSWIRE
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
01 Aug 2023 //
BUSINESSWIRE
Seres Therapeutics to Host Second Quarter 2023 Financial Results
01 Aug 2023 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Jul 2023 //
BUSINESSWIRE
Seres Therapeutics Named to TIME100 Most Influential Companies List
21 Jun 2023 //
BUSINESSWIRE
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data VOWST™
17 Jun 2023 //
BUSINESSWIRE
Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
09 Jun 2023 //
BUSINESSWIRE
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Jun 2023 //
BUSINESSWIRE
Seres and Nestlé Announce U.S. Commercial Availability of VOWST™
05 Jun 2023 //
BUSINESSWIRE
Seres Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
BUSINESSWIRE
Seres receives $125M payment from Nestlé
31 May 2023 //
ENDPTS
Seres Announces Receipt of $125 M Milestone From Nestlé Health Science
30 May 2023 //
BUSINESSWIRE
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
10 May 2023 //
BUSINESSWIRE
Seres & Nestlé Health Present Results from ECOSPOR IV Ph 3 of VOWST™
08 May 2023 //
BUSINESSWIRE
Seres Therapeutics to Host First Quarter 2023 Financial Results
05 May 2023 //
BUSINESSWIRE
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
27 Apr 2023 //
BUSINESSWIRE
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM
27 Apr 2023 //
BUSINESSWIRE
FDA approves first oral microbiome therapy from Nestle, Seres
27 Apr 2023 //
FIERCE PHARMA
Seres Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Apr 2023 //
BUSINESSWIRE
Seres to Participate in Oppenheimer 33rd Annual Healthcare Conference
09 Mar 2023 //
BUSINESSWIRE
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
BUSINESSWIRE
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
27 Feb 2023 //
BUSINESSWIRE
Seres’ Investigational SER-109 ECOSPOR IV Data Published in JAMA NETWORK OPEN
14 Feb 2023 //
BUSINESSWIRE
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study
08 Feb 2023 //
BUSINESSWIRE
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
BUSINESSWIRE
Seres Therapeutics to Host Third Quarter 2022 Financial Results
27 Oct 2022 //
BUSINESSWIRE
FDA mulls approving first oral microbiome therapy from Seres
26 Oct 2022 //
FIERCEBIOTECH
